st approval of combined cancer inhibitor drugs as a single pill. Last January 2014, the FDA approved the first combined inhibitor drug for melanoma: Dabrafcnib and Trametinib, designed to block certain BRAF enzyme pathway mutations and resistant mutations. In July 2014, the FDA approved combined inhibitors